EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

FoxO1 signaling in B cell malignancies and its therapeutic targeting

Krystof Hlavac, Petra Pavelkova, Laura Ondrisova, Marek Mraz iD

FEBS Letters · 2025-10 · 599 (20) · 2911-2931

DOI: 10.1002/1873-3468.15057 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift FEBS Letters, online erschienen am 12.11.2024. Verfasst von Krystof Hlavac und 3 weiteren Autor:innen. Beteiligte Einrichtung: Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Hauptthemen laut MEDLINE: Signal Transduction, Forkhead Box Protein O1, B-Lymphocytes, Lymphoma, B-Cell. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculty of Medicine, Masaryk University, National Institute for Cancer Research, Ministry of Health of the Czech Republic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

FoxO transcription factors (FoxO1, FoxO3a, FoxO4, FoxO6) are a highly evolutionary conserved subfamily of the ‘forkhead’ box proteins. They have traditionally been considered tumor suppressors, but FoxO1 also exhibits oncogenic properties. The complex nature of FoxO1 is illustrated by its various roles in B cell development and differentiation, immunoglobulin gene rearrangement and cell‐surface B cell receptor (BCR) structure, DNA damage control, cell cycle regulation, and germinal center reaction. FoxO1 is tightly regulated at a transcriptional (STAT3, HEB, EBF, FoxOs) and post‐transcriptional level (Akt, AMPK, CDK2, GSK3, IKKs, JNK, MAPK/Erk, SGK1, miRNA). In B cell malignancies, recurrent FoxO1 activating mutations (S22/T24) and aberrant nuclear export and activity have been described, underscoring the potential of its therapeutic inhibition. Here, we review FoxO1's roles across B cell and myeloid malignancies, namely acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt lymphoma (BL), Hodgkin lymphoma (HL), and multiple myeloma (MM). We also discuss preclinical evidence for FoxO1 targeting by currently available inhibitors (AS1708727, AS1842856, cpd10).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Signal TransductionForkhead Box Protein O1B-LymphocytesLymphoma, B-CellLeukemia, B-CellHumansAnimalsMolecular Targeted Therapy

Stichwörter der Autor:innen

AS1842856B cell developmentB cell malignanciesFoxO1FoxO1 inhibitorchronic lymphocytic leukemiacpd10leukemialymphomatargeted therapy

Substanzen

Forkhead Box Protein O1FOXO1 protein, human

Autor:innen und Institutionen

  • Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Brno, Czech Republic.

ORCID-Profile: Marek Mraz

Förderung

  • Faculty of Medicine, Masaryk University
  • National Institute for Cancer Research
  • Ministry of Health of the Czech Republic
  • Lékařská fakulta, Masarykova univerzita
  • Ministerstvo Zdravotnictví Ceské Republiky

Zitieren

APA

Hlavac, K., Pavelkova, P., Ondrisova, L., & Mraz, M. (2025). FoxO1 signaling in B cell malignancies and its therapeutic targeting. FEBS Letters, 599(20), 2911-2931. https://doi.org/10.1002/1873-3468.15057

Vancouver

Hlavac K, Pavelkova P, Ondrisova L, Mraz M. FoxO1 signaling in B cell malignancies and its therapeutic targeting. FEBS Letters. 2025;599(20):2911-2931. doi:10.1002/1873-3468.15057

BibTeX
@article{Hlavac2025,
  author = {Hlavac, Krystof and Pavelkova, Petra and Ondrisova, Laura and Mraz, Marek},
  title = {FoxO1 signaling in B cell malignancies and its therapeutic targeting},
  journal = {FEBS Letters},
  year = {2025},
  volume = {599},
  number = {20},
  pages = {2911--2931},
  doi = {10.1002/1873-3468.15057}
}
Kostenlos starten →